Pengenalan
Halaman ini menyediakan analisis menyeluruh tentang sejarah dagangan orang dalam yang diketahui Biotechnology Value Trading Fund OS LP. Orang dalam ialah pegawai, pengarah atau pelabur penting dalam syarikat. Adalah haram bagi orang dalam untuk membuat perdagangan dalam syarikat mereka berdasarkan maklumat khusus bukan awam. Ini tidak bermakna haram bagi mereka untuk membuat sebarang perdagangan dalam syarikat mereka sendiri. Tetapi mereka mesti melaporkan semua perdagangan kepada SEC melalui Borang 4. Walaupun terdapat sekatan ini, penyelidikan akademik menunjukkan bahawa orang dalam - secara amnya - cenderung untuk mengatasi prestasi pasaran dalam syarikat mereka sendiri.
Purata Keuntungan Perdagangan
Purata keuntungan perdagangan ialah purata pulangan semua pembelian pasaran terbuka yang dibuat oleh orang dalam dalam tempoh tiga tahun terakhir. Untuk mengira ini, kami memeriksa setiap pembelian pasaran terbuka yang tidak dirancang oleh orang dalam, tidak termasuk semua dagangan yang ditandakan sebagai sebahagian daripada pelan dagangan 10b5-1. Kami kemudian mengira prestasi purata dagangan tersebut sepanjang 3, 6 dan 12 bulan, dengan purata setiap tempoh tersebut untuk menjana metrik prestasi akhir bagi setiap dagangan. Akhir sekali, kami puratakan semua metrik prestasi untuk mengira metrik prestasi untuk orang dalam. Senarai ini hanya termasuk orang dalam yang telah membuat sekurang-kurangnya tiga dagangan dalam dua tahun lepas.
Jika keuntungan berdagang orang dalam ini ialah "N/A", maka orang dalam sama ada tidak membuat sebarang pembelian pasaran terbuka dalam tempoh tiga tahun terakhir, atau dagangan yang mereka buat adalah terlalu baru untuk mengira metrik prestasi yang boleh dipercayai.
Kekerapan Kemas Kini: Harian
Syarikat dengan Kedudukan Orang Dalam yang Dilaporkan
Pemfailan SEC menunjukkan Biotechnology Value Trading Fund OS LP telah melaporkan pegangan atau perdagangan dalam syarikat berikut:
Bagaimana Mentafsir Carta
Carta berikut menunjukkan prestasi saham sekuriti selepas setiap dagangan pasaran terbuka dan tidak dirancang yang dibuat oleh Biotechnology Value Trading Fund OS LP. Perdagangan tidak dirancang ialah dagangan yang tidak dibuat sebagai sebahagian daripada pelan dagangan 10b5-1. Prestasi saham dicatatkan sebagai perubahan peratus kumulatif dalam harga saham. Sebagai contoh, jika perdagangan orang dalam dibuat pada 1 Januari 2019, carta akan menunjukkan perubahan peratusan harian sekuriti kepada hari ini. Jika harga saham naik dari $10 kepada $15 pada masa ini, perubahan peratus terkumpul dalam harga saham ialah 50%. Perubahan dalam harga daripada $10 kepada $20 ialah 100% dan perubahan dalam harga $10 hingga $5 ialah -50%.
Secara dasarnya, kami cuba untuk menentukan sejauh mana dagangan orang dalam berkait rapat dengan pulangan berlebihan (positif atau negatif) dalam harga saham untuk melihat sama ada orang dalam menetapkan masa dagangan mereka untuk mendapat keuntungan daripada maklumat orang dalam. Pertimbangkan situasi di mana orang dalam melakukan perkara ini. Dalam keadaan ini, kami menjangkakan sama ada (a) pulangan positif selepas pembelian, atau (b) pulangan negatif selepas jualan. Dalam kes (a), carta PEMBELIAN akan menunjukkan satu siri keluk condong ke atas, menunjukkan pulangan positif selepas setiap transaksi pembelian. Dalam kes (b), carta JUALAN akan menunjukkan satu siri keluk condong ke bawah, menunjukkan pulangan negatif selepas setiap transaksi jualan.
Walau bagaimanapun, ini sahaja tidak cukup untuk membuat kesimpulan. Jika, sebagai contoh, harga saham syarikat berada dalam pendakian bukan disebabkan kitaran selama bertahun-tahun, maka kami menjangkakan semua plot selepas pembelian akan condong ke atas. Begitu juga, kemerosotan bukan disebabkan kitaran selama bertahun-tahun akan mengakibatkan plot pasca perdagangan condong ke bawah. Kedua-dua carta ini tidak akan mencadangkan aktiviti perdagangan orang dalam.
Penunjuk terkuat ialah keadaan di mana harga saham adalah sangat kitaran, dan terdapat kedua-dua isyarat positif dalam carta PEMBELIAN dan plot negatif pada carta JUALAN. Situasi ini akan sangat menunjukkan orang dalam yang menentukan masa perdagangan untuk kelebihan kewangan mereka.
Pembelian Orang Dalam CALA / Calithera Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam CALA / Calithera Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam CGEM / Cullinan Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam CGEM / Cullinan Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam CYTK / Cytokinetics, Incorporated - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam CYTK / Cytokinetics, Incorporated - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ELDN / Eledon Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ELDN / Eledon Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam EPIX / ESSA Pharma Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam EPIX / ESSA Pharma Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam FDMT / 4D Molecular Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam FDMT / 4D Molecular Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam IDYA / IDEAYA Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam IDYA / IDEAYA Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam INFIQ / Infinity Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam INFIQ / Infinity Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam KYMR / Kymera Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam KYMR / Kymera Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam MLTX / MoonLake Immunotherapeutics - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam MLTX / MoonLake Immunotherapeutics - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam MRUS / Merus N.V. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam MRUS / Merus N.V. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam OLMA / Olema Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam OLMA / Olema Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam VSTM / Verastem, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam VSTM / Verastem, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam XENE / Xenon Pharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam XENE / Xenon Pharmaceuticals Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam CALA / Calithera Biosciences, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Sejarah Dagangan Orang Dalam
Jadual ini menunjukkan senarai lengkap dagangan orang dalam yang dibuat oleh Biotechnology Value Trading Fund OS LP seperti yang didedahkan kepada Suruhanjaya Bursa Sekuriti (SEC).
Tarikh Fail | Tarikh Tran | Borang | Simbol Saham | Sekuriti | Kod | Saham | Baki Saham | Peratus Ubah |
Saham harga |
Tran Nilai |
Baki Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -11 | 560,797 | 0.00 | 1.88 | -21 | 1,053,121 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -66 | 4,726,743 | 0.00 | 1.88 | -124 | 8,876,351 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -79 | 6,194,145 | 0.00 | 1.88 | -148 | 11,631,985 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 203,336 | 560,808 | 56.88 | 0.00 | 20 | 56 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,235,030 | 4,726,809 | 35.37 | 0.00 | 124 | 473 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,481,634 | 6,194,224 | 31.44 | 0.00 | 148 | 619 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,780 | 353,412 | 19.95 | 44.00 | 2,586,320 | 15,550,128 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 115,783 | 2,219,858 | 5.50 | 44.00 | 5,094,452 | 97,673,752 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142,604 | 2,798,795 | 5.37 | 44.00 | 6,274,576 | 123,146,980 | |
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 56,079 | 62,383 | 889.58 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 556,617 | 593,740 | 1,499.39 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 657,308 | 707,116 | 1,319.68 | ||||
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -265,316 | 1,267,545 | -17.31 | 27.10 | -7,190,064 | 34,350,470 | |
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -127,407 | 1,322,758 | -8.79 | 27.10 | -3,452,730 | 35,846,742 | |
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -855,211 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -6,777,935 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -8,679,726 | 0 | -100.00 | ||||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -149,975 | 0 | -100.00 | 26.10 | -3,914,348 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -75,287 | 0 | -100.00 | 26.10 | -1,964,991 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -85,776 | 1,532,861 | -5.30 | 26.10 | -2,238,754 | 40,007,672 | |
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -339,679 | 1,450,165 | -18.98 | 26.10 | -8,865,622 | 37,849,306 | |
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -22,740 | 347,970 | -6.13 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -161,810 | 2,003,966 | -7.47 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -235,450 | 2,655,977 | -8.14 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 29,648 | 38,961 | 318.35 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 174,958 | 282,223 | 163.11 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 234,323 | 371,916 | 170.30 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -153,441 | 370,710 | -29.27 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,418,736 | 2,165,776 | -39.58 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,797,527 | 2,891,427 | -38.34 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -240,000 | 87,911 | -73.19 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -2,378,000 | 662,970 | -78.20 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -3,062,000 | 830,237 | -78.67 | ||||
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -64,617 | 176,692 | -26.78 | 14.30 | -924,023 | 2,526,696 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -396,963 | 1,367,257 | -22.50 | 14.30 | -5,676,571 | 19,551,775 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -538,420 | 1,794,218 | -23.08 | 14.30 | -7,699,406 | 25,657,317 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -132,549 | 1,287,768 | -9.33 | 50.00 | -6,627,662 | 64,390,460 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -836,862 | 8,168,838 | -9.29 | 50.00 | -41,844,439 | 408,454,970 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1,030,589 | 10,235,089 | -9.15 | 50.00 | -51,531,099 | 511,770,826 | |
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,892,237 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,040,970 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
327,911 | ||||||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,431 | 220,460 | 52.01 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 821,121 | 2,633,679 | 45.30 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,031,385 | 3,361,803 | 44.26 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -341,547 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -185,388 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,076,085 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,367,838 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,870,985 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,734,960 | 0 | -100.00 | ||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
8,679,726 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
6,777,935 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
855,211 | ||||||||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -896,366 | 0 | -100.00 | 12.45 | -11,159,757 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -7,290,667 | 0 | -100.00 | 12.45 | -90,768,804 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -8,974,245 | 0 | -100.00 | 12.45 | -111,729,350 | ||
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 16,143 | 548,938 | 3.03 | 5.38 | 86,909 | 2,955,318 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 125,909 | 4,308,573 | 3.01 | 5.38 | 677,856 | 23,196,064 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 153,693 | 5,309,432 | 2.98 | 5.38 | 827,437 | 28,584,389 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 47,712 | 532,795 | 9.84 | 5.00 | 238,555 | 2,663,922 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 390,507 | 4,182,664 | 10.30 | 5.00 | 1,952,496 | 20,912,902 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 493,337 | 5,155,739 | 10.58 | 5.00 | 2,466,636 | 25,778,179 | |
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
1,204,412 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
912,776 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
104,257 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
8,974,245 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
7,290,667 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
896,366 | ||||||||
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,106 | 294,632 | 3.55 | 14.07 | 142,180 | 4,145,148 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 83,708 | 2,104,075 | 4.14 | 14.07 | 1,177,679 | 29,602,021 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 103,885 | 2,656,191 | 4.07 | 14.07 | 1,461,548 | 37,369,686 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,772 | 284,526 | 10.39 | 11.64 | 311,744 | 3,313,135 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 132,016 | 2,020,367 | 6.99 | 11.64 | 1,537,247 | 23,525,961 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,618 | 2,552,306 | 2.31 | 11.64 | 670,927 | 29,720,072 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 72,479 | 485,083 | 17.57 | 3.60 | 260,924 | 1,746,299 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 492,251 | 3,792,157 | 14.92 | 3.60 | 1,772,104 | 13,651,765 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 218,979 | 4,662,402 | 4.93 | 3.60 | 788,324 | 16,784,647 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 52,801 | 524,151 | 11.20 | 9.84 | 519,562 | 5,157,646 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 677,853 | 3,584,512 | 23.32 | 9.84 | 6,670,074 | 35,271,598 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 775,278 | 4,688,954 | 19.81 | 9.84 | 7,628,736 | 46,139,307 | |
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -43,139 | 0 | -100.00 | 9.10 | -392,565 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -1,526,147 | 0 | -100.00 | 9.10 | -13,887,938 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -702,505 | 0 | -100.00 | 9.10 | -6,392,796 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -2,595,239 | 0 | -100.00 | 9.10 | -23,616,675 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -3,989,130 | 0 | -100.00 | 9.10 | -36,301,083 | ||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
11,007,420 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
8,581,171 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
744,966 | ||||||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -462,605 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -2,929,660 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -4,018,253 | 0 | -100.00 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 86,341 | 145,029 | 147.12 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 837,146 | 1,812,558 | 85.82 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,055,445 | 2,330,418 | 82.78 | ||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
4,018,253 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,801,529 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,929,660 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,130,657 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
462,605 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
241,755 | ||||||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -300,000 | 64,161 | -82.38 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -2,600,000 | 392,808 | -86.87 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -3,500,000 | 558,854 | -86.23 | ||||
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 15,912 | 1,888,351 | 0.85 | 31.24 | 497,132 | 58,996,995 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2,985 | 2,494,688 | 0.12 | 31.24 | 93,259 | 77,940,539 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,149 | 1,872,439 | 0.60 | 29.89 | 333,209 | 55,961,397 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,961 | 2,491,703 | 0.44 | 29.89 | 327,590 | 74,469,278 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,573 | 1,618,637 | 0.10 | 21.98 | 34,577 | 35,580,393 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,676 | 1,789,844 | 0.09 | 21.98 | 36,841 | 39,343,814 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 15,670 | 1,617,064 | 0.98 | 18.39 | 288,096 | 29,730,045 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,330 | 1,788,168 | 0.19 | 18.39 | 61,223 | 32,875,826 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 9,597 | 241,309 | 4.14 | 4.11 | 39,430 | 991,442 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 87,831 | 1,764,220 | 5.24 | 4.11 | 360,862 | 7,248,474 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 116,635 | 2,332,638 | 5.26 | 4.11 | 479,207 | 9,583,876 | |
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
2,216,003 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
1,676,389 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
231,712 | ||||||||
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 54,857 | 341,547 | 19.13 | 5.83 | 319,816 | 1,991,219 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 685,330 | 2,076,085 | 49.28 | 5.83 | 3,995,474 | 12,103,576 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 970,171 | 2,870,985 | 51.04 | 5.83 | 5,656,097 | 16,737,843 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 678 | 1,601,394 | 0.04 | 16.89 | 11,452 | 27,047,865 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,004 | 1,784,838 | 0.06 | 16.89 | 16,958 | 30,146,271 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,021 | 1,600,716 | 0.19 | 16.83 | 50,849 | 26,942,771 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,339 | 1,783,834 | 0.19 | 16.83 | 56,201 | 30,024,959 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,885 | 1,597,695 | 0.62 | 16.50 | 163,073 | 26,357,174 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,715 | 1,780,495 | 0.38 | 16.50 | 110,777 | 29,372,826 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,396 | 1,773,780 | 0.76 | 17.89 | 239,618 | 31,728,135 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,897 | 1,587,810 | 0.69 | 17.89 | 194,918 | 28,401,634 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,575 | 1,576,913 | 0.35 | 17.96 | 100,138 | 28,324,511 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 26,441 | 1,571,338 | 1.71 | 17.25 | 456,044 | 27,101,809 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,117 | 257,754 | 11.76 | 26.00 | 705,042 | 6,701,604 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 233,362 | 1,861,290 | 14.33 | 26.00 | 6,067,412 | 48,393,540 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 285,046 | 2,480,742 | 12.98 | 26.00 | 7,411,196 | 64,499,292 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 1,519,999 | 1,526,147 | 24,723.47 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -1,289,434 | 6,148 | -99.53 | 6.12 | -7,891,336 | 37,626 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 682,666 | 702,505 | 3,441.03 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -469,040 | 19,839 | -95.94 | 6.12 | -2,870,525 | 121,415 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 2,426,666 | 2,595,239 | 1,439.53 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -2,890,723 | 168,573 | -94.49 | 6.12 | -17,691,225 | 1,031,667 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 3,754,000 | 3,989,130 | 1,596.56 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -3,850,803 | 235,130 | -94.25 | 6.12 | -23,566,914 | 1,438,996 | |
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
4,712,590 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
3,491,779 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
357,472 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
2,132,411 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
1,570,857 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
209,716 | ||||||||
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 6,168 | 412,604 | 1.52 | 12.73 | 78,519 | 5,252,449 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 68,327 | 3,299,906 | 2.11 | 12.73 | 869,803 | 42,007,803 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 74,666 | 4,443,423 | 1.71 | 12.73 | 950,498 | 56,564,775 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 41,417 | 2,906,659 | 1.45 | 4.03 | 167,097 | 11,726,916 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 158,583 | 3,913,676 | 4.22 | 4.03 | 639,803 | 15,789,726 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 20 | 406,436 | 0.00 | 13.21 | 264 | 5,369,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,040 | 3,231,579 | 0.09 | 13.21 | 40,164 | 42,694,975 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,809 | 4,368,757 | 0.09 | 13.21 | 50,324 | 57,719,144 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 31,903 | 406,416 | 8.52 | 12.29 | 391,960 | 4,993,227 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 258,797 | 3,228,539 | 8.71 | 12.29 | 3,179,580 | 39,665,830 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 353,344 | 4,364,948 | 8.81 | 12.29 | 4,341,184 | 53,627,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 61,156 | 374,513 | 19.52 | 11.68 | 714,449 | 4,375,211 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 464,235 | 2,969,742 | 18.53 | 11.68 | 5,423,379 | 34,693,714 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 660,654 | 4,011,604 | 19.72 | 11.68 | 7,718,024 | 46,865,163 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 44,746 | 364,161 | 14.01 | 11.00 | 492,179 | 4,005,553 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 301,009 | 2,992,808 | 11.18 | 11.00 | 3,310,918 | 32,919,092 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 405,641 | 4,058,854 | 11.10 | 11.00 | 4,461,808 | 44,644,959 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 3,223 | 230,637 | 1.42 | 14.78 | 47,645 | 3,409,461 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,353 | 1,627,928 | 1.65 | 14.78 | 389,571 | 24,065,334 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 35,793 | 2,195,696 | 1.66 | 14.78 | 529,121 | 32,458,535 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,642 | 227,414 | 4.91 | 14.21 | 151,229 | 3,231,689 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 90,372 | 1,601,575 | 5.98 | 14.21 | 1,284,240 | 22,759,342 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 123,043 | 2,159,903 | 6.04 | 14.21 | 1,748,515 | 30,693,518 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37 | 216,772 | 0.02 | 14.00 | 518 | 3,034,678 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,180 | 1,511,203 | 0.28 | 14.00 | 58,517 | 21,155,935 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5,883 | 2,036,860 | 0.29 | 14.00 | 82,358 | 28,514,818 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 5,730 | 313,357 | 1.86 | 8.50 | 48,705 | 2,663,534 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 189,882 | 2,505,507 | 8.20 | 8.50 | 1,613,997 | 21,296,810 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 224,388 | 3,350,950 | 7.18 | 8.50 | 1,907,298 | 28,483,075 | |
2022-05-20 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 8,996 | 8,996 | |||||
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 17,744 | 319,415 | 5.88 | 9.14 | 162,091 | 2,917,856 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 38,558 | 2,691,799 | 1.45 | 9.14 | 352,227 | 24,589,584 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 53,598 | 3,653,213 | 1.49 | 9.14 | 489,618 | 33,372,101 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 457,001 | 2,653,241 | 20.81 | 9.06 | 4,140,429 | 24,038,363 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 542,999 | 3,599,615 | 17.76 | 9.06 | 4,919,571 | 32,612,512 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,131 | 216,735 | 1.94 | 19.26 | 79,542 | 4,173,232 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 40,659 | 1,507,023 | 2.77 | 19.26 | 782,889 | 29,017,728 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55,210 | 2,030,977 | 2.79 | 19.26 | 1,063,069 | 39,106,462 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,066 | 212,604 | 1.95 | 19.60 | 79,690 | 4,166,847 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 70,439 | 1,466,364 | 5.05 | 19.60 | 1,380,541 | 28,739,415 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 75,495 | 1,975,767 | 3.97 | 19.60 | 1,479,634 | 38,723,255 | |
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
11,265,678 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
9,005,699 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
1,420,317 | ||||||||
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 9,402 | 2,196,240 | 0.43 | 10.75 | 101,071 | 23,609,360 | |
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 266,598 | 3,056,616 | 9.56 | 10.75 | 2,865,902 | 32,858,316 | |
2022-03-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
10,753,294 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
7,883,287 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
994,353 | ||||||||
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,323 | 1,395,925 | 1.04 | 40.70 | 582,946 | 56,814,148 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20,085 | 1,900,272 | 1.07 | 40.70 | 817,460 | 77,341,070 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37,859 | 1,381,602 | 2.82 | 38.33 | 1,451,207 | 52,959,430 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,042 | 1,880,187 | 3.19 | 38.33 | 2,224,860 | 72,071,140 | |
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
1,274,973 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
975,412 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
58,688 | ||||||||
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 114,726 | 1,343,743 | 9.33 | 37.76 | 4,332,455 | 50,744,439 | |
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 158,041 | 1,822,145 | 9.50 | 37.76 | 5,968,181 | 68,810,573 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 7,899 | 307,627 | 2.64 | 14.10 | 111,376 | 4,337,541 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 412,264 | 2,315,625 | 21.66 | 14.10 | 5,812,922 | 32,650,312 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 577,798 | 3,126,562 | 22.67 | 14.10 | 8,146,952 | 44,084,524 | |
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,790,018 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,186,838 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
301,671 | ||||||||
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,806 | 185,388 | 8.68 | 12.00 | 177,672 | 2,224,656 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 226,079 | 1,367,838 | 19.80 | 12.00 | 2,712,948 | 16,414,056 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 255,500 | 1,734,960 | 17.27 | 12.00 | 3,066,000 | 20,819,520 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 61,343 | 1,141,759 | 5.68 | 12.00 | 736,018 | 13,699,281 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 35,268 | 471,350 | 8.09 | 9.39 | 331,177 | 4,426,118 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 341,977 | 2,865,242 | 13.55 | 9.39 | 3,211,267 | 26,905,482 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 362,430 | 3,755,093 | 10.68 | 9.39 | 3,403,326 | 35,261,450 | |
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
2,548,764 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
1,903,361 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
299,728 | ||||||||
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -8,929 | 232,747 | -3.69 | 27.79 | -248,106 | 6,467,225 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -58,327 | 1,520,405 | -3.69 | 27.79 | -1,620,703 | 42,246,734 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -80,011 | 2,085,664 | -3.69 | 27.79 | -2,223,226 | 57,953,303 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -69,534 | 241,676 | -22.34 | 27.53 | -1,914,348 | 6,653,606 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -384,914 | 1,578,732 | -19.60 | 27.53 | -10,597,106 | 43,464,229 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -530,999 | 2,165,675 | -19.69 | 27.53 | -14,618,987 | 59,623,415 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 590 | 170,582 | 0.35 | 13.94 | 8,226 | 2,378,357 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,102 | 1,080,416 | 0.38 | 13.94 | 57,193 | 15,063,808 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,341 | 1,479,460 | 0.43 | 13.94 | 88,410 | 20,627,519 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,512 | 169,992 | 13.72 | 16.49 | 338,243 | 2,803,168 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 158,511 | 1,076,314 | 17.27 | 16.49 | 2,613,846 | 17,748,418 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 213,246 | 1,473,119 | 16.93 | 16.49 | 3,516,427 | 24,291,732 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -150,805 | 311,210 | -32.64 | 20.75 | -3,129,204 | 6,457,608 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -928,739 | 1,963,646 | -32.11 | 20.75 | -19,271,334 | 40,745,654 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -1,106,478 | 2,696,674 | -29.09 | 20.75 | -22,959,418 | 55,955,986 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,458 | 208,538 | 15.16 | 47.00 | 1,290,526 | 9,801,286 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 211,711 | 1,229,017 | 20.81 | 47.00 | 9,950,417 | 57,763,799 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 304,997 | 1,664,104 | 22.44 | 47.00 | 14,334,859 | 78,212,888 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,980 | 149,480 | 12.82 | 15.25 | 258,945 | 2,279,570 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 106,627 | 917,803 | 13.14 | 15.25 | 1,626,062 | 13,996,496 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 146,116 | 1,259,873 | 13.12 | 15.25 | 2,228,269 | 19,213,063 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,018 | 132,500 | 17.80 | 15.65 | 313,282 | 2,073,625 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 124,804 | 811,176 | 18.18 | 15.65 | 1,953,183 | 12,694,904 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 172,457 | 1,113,757 | 18.32 | 15.65 | 2,698,952 | 17,430,297 | |
2021-06-21 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20,063 | 20,063 | |||||
2021-05-26 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 129 | 112,482 | 0.11 | 15.90 | 2,050 | 1,787,924 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 513 | 686,372 | 0.07 | 15.90 | 8,154 | 10,910,020 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 719 | 941,300 | 0.08 | 15.90 | 11,429 | 14,962,152 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 7,592 | 112,353 | 7.25 | 15.94 | 121,032 | 1,791,132 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 48,152 | 685,859 | 7.55 | 15.94 | 767,639 | 10,933,964 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 66,242 | 940,581 | 7.58 | 15.94 | 1,056,030 | 14,994,742 | |
2021-05-21 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 5,101 | 5,101 | |||||
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,115 | 104,761 | 1.08 | 15.88 | 17,711 | 1,664,055 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,962 | 637,707 | 1.10 | 15.88 | 110,586 | 10,129,529 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,191 | 874,339 | 1.06 | 15.88 | 145,993 | 13,888,263 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 11,946 | 103,646 | 13.03 | 16.65 | 198,901 | 1,725,706 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,640 | 630,745 | 13.63 | 16.65 | 1,259,406 | 10,501,904 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 103,611 | 865,148 | 13.61 | 16.65 | 1,725,123 | 14,404,714 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,474 | 91,700 | 3.94 | 14.26 | 49,544 | 1,307,780 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,721 | 555,105 | 4.27 | 14.26 | 324,036 | 7,916,630 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 31,805 | 761,537 | 4.36 | 14.26 | 453,587 | 10,860,660 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -134,515 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -152,176 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -17,390 | 152,176 | -10.26 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -837,397 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -553,359 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -84,350 | 553,359 | -13.23 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,068,554 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -832,261 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -115,293 | 832,261 | -12.17 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 134,515 | 286,691 | 88.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 152,176 | 152,176 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 17,390 | 17,390 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 837,397 | 1,390,756 | 151.33 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 553,359 | 553,359 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 84,350 | 84,350 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 1,068,554 | 1,900,815 | 128.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 832,261 | 832,261 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 115,293 | 115,293 | |||||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 17 | 17 | 25,000.00 | 425,000 | 425,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 239 | 239 | 25,000.00 | 5,975,000 | 5,975,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 344 | 344 | 25,000.00 | 8,600,000 | 8,600,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 5,171 | 488,879 | 1.07 | 2.50 | 12,928 | 1,222,198 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 950,016 | 3,059,296 | 45.04 | 2.50 | 2,375,040 | 7,648,240 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 1,044,813 | 4,085,933 | 34.36 | 2.50 | 2,612,032 | 10,214,832 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -81,903 | 149,975 | -35.32 | 38.36 | -3,141,799 | 5,753,041 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -84,250 | 75,287 | -52.81 | 38.36 | -3,231,830 | 2,888,009 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -205,807 | 1,544,897 | -11.76 | 38.36 | -7,894,757 | 59,262,249 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -279,740 | 1,760,384 | -13.71 | 38.36 | -10,730,826 | 67,528,330 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 26,894 | 462,015 | 6.18 | 19.75 | 531,156 | 9,124,796 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 108,106 | 2,892,385 | 3.88 | 19.75 | 2,135,094 | 57,124,604 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 165,000 | 3,803,152 | 4.54 | 19.75 | 3,258,750 | 75,112,252 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 7,744 | 435,121 | 1.81 | 22.75 | 176,176 | 9,899,003 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 71,756 | 3,638,152 | 2.01 | 22.75 | 1,632,449 | 82,767,958 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 1,171 | 427,377 | 0.27 | 23.00 | 26,933 | 9,829,500 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 195,768 | 2,784,279 | 7.56 | 23.00 | 4,502,586 | 64,037,303 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,061 | 3,566,396 | 1.51 | 23.00 | 1,220,382 | 82,025,681 | |
2021-03-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
3,372,098 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
2,484,643 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
405,344 | ||||||||
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -152,127 | 534,847 | -22.14 | 5.37 | -816,709 | 2,871,380 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -892,467 | 3,279,831 | -21.39 | 5.37 | -4,791,298 | 17,608,101 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,215,491 | 4,448,421 | -21.46 | 5.37 | -6,525,485 | 23,881,793 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -4,325 | 233,150 | -1.82 | 18.00 | -77,850 | 4,196,700 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -16,850 | 1,188,131 | -1.40 | 18.00 | -303,300 | 21,386,358 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -25,234 | 1,642,186 | -1.51 | 18.00 | -454,212 | 29,559,348 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -568,019 | 686,974 | -45.26 | 4.14 | -2,350,917 | 2,843,248 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,458,838 | 4,172,298 | -37.08 | 4.14 | -10,176,639 | 17,268,307 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,821,663 | 5,663,912 | -33.25 | 4.14 | -11,678,299 | 23,441,799 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 43,422 | 426,206 | 11.34 | 24.75 | 1,074,694 | 10,548,598 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 343,444 | 2,588,511 | 15.30 | 24.75 | 8,500,239 | 64,065,647 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 457,814 | 3,513,335 | 14.98 | 24.75 | 11,330,896 | 86,955,041 | |
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -1,757 | 6,758 | -20.63 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -9,169 | 39,693 | -18.77 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -11,776 | 52,145 | -18.42 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -35 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -203 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -273 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 97,615 | 113,152 | 628.27 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 1,944 | 15,537 | 14.30 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 509,410 | 598,624 | 571.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 11,278 | 89,214 | 14.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 654,215 | 771,780 | 556.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 15,166 | 117,565 | 14.81 | ||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,945,743 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,164,406 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
358,450 | ||||||||
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 45,032 | 2,245,067 | 2.05 | 16.05 | 722,764 | 36,033,325 | |
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 114,968 | 3,055,521 | 3.91 | 16.05 | 1,845,236 | 49,041,112 | |
2020-12-15 |
|
4 | XOMA |
XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock |
P - Purchase | 200,000 | 200,000 | 25.00 | 5,000,000 | 5,000,000 | ||
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -25,486 | 463,244 | -5.21 | 18.00 | -458,748 | 8,338,392 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -166,194 | 2,760,185 | -5.68 | 18.00 | -2,991,492 | 49,683,330 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -239,274 | 3,811,271 | -5.91 | 18.00 | -4,306,932 | 68,602,878 | |
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
4,050,545 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,926,379 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
488,730 | ||||||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -93 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -551 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -740 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -73,399 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -522,403 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -760,155 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -101,784 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673,281 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -889,186 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -185,908 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -881,156 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1,129,404 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 74,991 | 436,082 | 20.77 | 19.00 | 1,424,829 | 8,285,558 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 73,399 | 361,091 | 25.51 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 101,784 | 287,692 | 54.75 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 185,908 | 185,908 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 446,425 | 2,523,265 | 21.50 | 19.00 | 8,482,075 | 47,942,035 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 522,403 | 2,076,840 | 33.61 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 673,281 | 1,554,437 | 76.41 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 881,156 | 881,156 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 613,918 | 3,392,663 | 22.09 | 19.00 | 11,664,442 | 64,460,597 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 760,155 | 2,778,745 | 37.66 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 889,186 | 2,018,590 | 78.73 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 1,129,404 | 1,129,404 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
3,822,766 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,777,320 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
465,924 | ||||||||
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -502,649 | 81,263 | -86.08 | 20.19 | -10,146,825 | 1,640,432 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,949,477 | 485,513 | -85.87 | 20.19 | -59,540,207 | 9,800,905 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -3,941,214 | 670,695 | -85.46 | 20.19 | -79,560,105 | 13,539,119 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 86,090 | 630,453 | 15.81 | 2.60 | 223,834 | 1,639,178 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 506,155 | 3,712,350 | 15.79 | 2.60 | 1,316,003 | 9,652,110 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 674,492 | 4,980,812 | 15.66 | 2.60 | 1,753,679 | 12,950,111 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,334 | 583,912 | 0.40 | 4.98 | 11,633 | 2,910,217 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,436 | 3,434,990 | 0.30 | 4.98 | 52,013 | 17,119,990 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 17,230 | 4,611,909 | 0.37 | 4.98 | 85,874 | 22,985,754 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,355 | 581,578 | 2.71 | 4.88 | 74,997 | 2,840,543 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 143,403 | 3,424,554 | 4.37 | 4.88 | 700,409 | 16,726,207 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 257,804 | 4,594,679 | 5.94 | 4.88 | 1,259,166 | 22,441,331 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,472 | 544,363 | 2.93 | 2.75 | 42,548 | 1,496,998 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 250,755 | 3,206,195 | 8.48 | 2.75 | 689,576 | 8,817,036 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 666,385 | 4,306,320 | 18.31 | 2.75 | 1,832,559 | 11,842,380 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 25,107 | 566,223 | 4.64 | 5.04 | 126,414 | 2,850,933 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,352 | 3,281,151 | 5.21 | 5.04 | 817,442 | 16,520,595 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 157,782 | 4,336,875 | 3.78 | 5.04 | 794,432 | 21,836,166 | |
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
102,400 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
77,936 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
13,595 | ||||||||
2020-09-24 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32 | 541,116 | 0.01 | 3.80 | 122 | 2,055,537 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,201 | 1,750,704 | 0.41 | 18.20 | 131,057 | 31,862,463 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,888 | 2,040,124 | 0.49 | 18.20 | 179,960 | 37,129,849 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,991 | 1,743,503 | 0.29 | 18.45 | 92,062 | 32,160,133 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,960 | 2,030,236 | 0.34 | 18.45 | 128,382 | 37,449,124 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,069 | 1,738,512 | 0.58 | 18.39 | 185,120 | 31,962,717 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 12,259 | 2,023,276 | 0.61 | 18.39 | 225,383 | 37,198,132 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 10,258 | 382,784 | 2.75 | 11.75 | 120,532 | 4,497,712 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 58,745 | 2,200,035 | 2.74 | 11.75 | 690,254 | 25,850,411 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 77,751 | 2,940,553 | 2.72 | 11.75 | 913,574 | 34,551,498 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 12,816 | 372,526 | 3.56 | 11.10 | 142,235 | 4,134,368 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 76,374 | 2,141,290 | 3.70 | 11.10 | 847,614 | 23,764,465 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 100,461 | 2,862,802 | 3.64 | 11.10 | 1,114,936 | 31,771,949 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,830 | 1,728,443 | 0.22 | 18.77 | 71,891 | 32,443,912 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,907 | 2,011,017 | 0.19 | 18.77 | 73,337 | 37,747,996 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 14,339 | 359,710 | 4.15 | 11.17 | 160,167 | 4,017,961 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 82,740 | 2,064,916 | 4.17 | 11.17 | 924,206 | 23,065,112 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 104,827 | 2,762,341 | 3.94 | 11.17 | 1,170,918 | 30,855,349 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,672 | 1,724,613 | 0.45 | 18.87 | 144,741 | 32,536,721 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,900 | 2,007,110 | 0.50 | 18.87 | 186,774 | 37,866,338 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,862 | 1,716,941 | 0.40 | 18.48 | 126,814 | 31,730,100 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,143 | 1,997,210 | 0.46 | 18.48 | 168,968 | 36,909,639 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 922 | 1,710,079 | 0.05 | 19.17 | 17,676 | 32,785,464 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,122 | 1,988,067 | 0.06 | 19.17 | 21,511 | 38,115,022 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -180,686 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,000,955 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,336,390 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 67,791 | 181,081 | 59.84 | 20.00 | 1,355,820 | 3,621,620 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 113,290 | 113,290 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 389,709 | 1,017,307 | 62.10 | 20.00 | 7,794,180 | 20,346,140 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 627,598 | 627,598 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 521,193 | 1,359,109 | 62.20 | 20.00 | 10,423,860 | 27,182,180 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 837,916 | 837,916 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | -40,127 | 40,127 | -50.00 | ||||
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,244 | 1,709,157 | 0.13 | 19.74 | 44,308 | 33,747,305 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,443 | 1,986,945 | 0.17 | 19.74 | 67,982 | 39,232,229 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,179 | 1,706,913 | 0.30 | 19.31 | 100,003 | 32,959,295 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,504 | 1,983,502 | 0.33 | 19.31 | 125,588 | 38,300,035 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,607 | 1,701,734 | 0.09 | 19.32 | 31,050 | 32,880,224 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,198 | 1,976,998 | 0.47 | 19.32 | 177,720 | 38,198,765 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 158 | 3,547 | 4.66 | 35.79 | 5,655 | 126,947 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 905 | 20,390 | 4.64 | 35.79 | 32,390 | 729,758 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 1,205 | 27,265 | 4.62 | 35.79 | 43,127 | 975,814 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,772 | 1,967,800 | 0.09 | 19.12 | 33,881 | 37,624,336 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,496 | 1,966,028 | 0.18 | 19.70 | 68,877 | 38,733,897 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 895 | 1,962,532 | 0.05 | 19.27 | 17,246 | 37,816,814 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,922 | 1,961,637 | 1.13 | 18.69 | 409,810 | 36,670,842 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,050 | 1,939,715 | 0.05 | 17.80 | 18,693 | 34,533,134 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,050 | 1,938,665 | 0.21 | 17.34 | 70,233 | 33,619,359 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 81 | 237,475 | 0.03 | 13.32 | 1,079 | 3,162,312 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 929 | 1,204,981 | 0.08 | 13.32 | 12,371 | 16,046,009 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,521 | 1,667,420 | 0.09 | 13.32 | 20,254 | 22,204,032 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,354 | 237,394 | 0.57 | 13.93 | 18,868 | 3,308,014 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 7,854 | 1,204,052 | 0.66 | 13.93 | 109,443 | 16,778,103 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,524 | 1,665,899 | 0.64 | 13.93 | 146,649 | 23,213,803 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 6,769 | 236,040 | 2.95 | 14.39 | 97,403 | 3,396,498 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 39,052 | 1,196,198 | 3.37 | 14.39 | 561,939 | 17,212,691 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 52,443 | 1,655,375 | 3.27 | 14.39 | 754,629 | 23,820,019 | |
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 6,967 | 345,371 | 2.06 | 15.20 | 105,898 | 5,249,639 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 33,321 | 1,982,176 | 1.71 | 15.20 | 506,479 | 30,129,075 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 46,966 | 2,657,514 | 1.80 | 15.20 | 713,883 | 40,394,213 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 94,101 | 338,404 | 38.52 | 14.00 | 1,317,414 | 4,737,656 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 561,966 | 1,948,855 | 40.52 | 14.00 | 7,867,524 | 27,283,970 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 806,443 | 2,610,548 | 44.70 | 14.00 | 11,290,202 | 36,547,672 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -192,250 | 480,432 | -28.58 | 6.00 | -1,153,500 | 2,882,592 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,064,332 | 2,766,561 | -27.78 | 6.00 | -6,385,992 | 16,599,366 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,027,016 | 3,712,340 | -21.67 | 6.00 | -6,162,096 | 22,274,040 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,476 | 541,084 | 0.83 | 4.10 | 18,352 | 2,218,444 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,810 | 3,118,799 | 1.29 | 4.10 | 163,221 | 12,787,076 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 249,301 | 4,179,093 | 6.34 | 4.10 | 1,022,134 | 17,134,281 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -597 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -656 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 596,813 | 1,700,127 | 54.09 | 13.00 | 7,758,569 | 22,101,651 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 655,959 | 1,934,615 | 51.30 | 13.00 | 8,527,467 | 25,149,995 | |
2020-03-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,264 | 1,278,656 | 0.65 | 17.20 | 142,129 | 21,991,093 | |
2020-03-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,439 | 1,270,392 | 0.35 | 14.52 | 64,475 | 18,451,936 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,113 | 1,265,953 | 0.64 | 15.73 | 127,648 | 19,918,125 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,164 | 1,257,840 | 0.81 | 15.73 | 159,916 | 19,790,351 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 100,000 | 1,247,676 | 8.71 | 18.34 | 1,834,090 | 22,883,501 | |
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 12 | 12 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 87 | 191 | 83.65 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 841 | 1,250 | 205.62 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 981 | 1,594 | 160.03 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 104 | 104 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -104 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 409 | 409 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -409 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 613 | 613 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -613 | 0 | -100.00 | ||||
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -74,893 | 424,419 | -15.00 | 15.79 | -1,182,321 | 6,700,218 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -510,793 | 2,350,829 | -17.85 | 15.79 | -8,063,787 | 37,112,067 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -486,344 | 3,131,432 | -13.44 | 15.79 | -7,677,815 | 49,435,291 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 19,727 | 244,303 | 8.78 | 16.15 | 318,591 | 3,945,493 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 112,561 | 1,386,889 | 8.83 | 16.15 | 1,817,860 | 22,398,257 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 146,442 | 1,804,105 | 8.83 | 16.15 | 2,365,038 | 29,136,296 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 5,406 | 224,576 | 2.47 | 14.98 | 80,973 | 3,363,789 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 25,108 | 1,274,328 | 2.01 | 14.98 | 376,078 | 19,087,395 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,448 | 1,657,663 | 3.33 | 14.98 | 800,566 | 24,829,139 | |
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32,606 | 536,608 | 6.47 | 4.05 | 132,054 | 2,173,262 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 201,096 | 3,078,989 | 6.99 | 4.05 | 814,439 | 12,469,905 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 281,318 | 3,929,792 | 7.71 | 4.05 | 1,139,338 | 15,915,658 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 165,961 | 1,103,314 | 17.71 | 22.00 | 3,651,142 | 24,272,908 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 207,234 | 1,147,676 | 22.04 | 22.00 | 4,559,148 | 25,248,872 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -35,888 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -190,899 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -245,481 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 35,888 | 159,537 | 29.02 | 22.00 | 789,536 | 3,509,814 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 190,899 | 937,353 | 25.57 | 22.00 | 4,199,778 | 20,621,766 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 245,481 | 940,442 | 35.32 | 22.00 | 5,400,582 | 20,689,724 | |
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 8,506 | 499,312 | 1.73 | 9.52 | 80,935 | 4,750,954 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 49,804 | 2,861,622 | 1.77 | 9.52 | 473,885 | 27,228,333 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 60,103 | 3,617,776 | 1.69 | 9.52 | 571,880 | 34,423,139 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,030 | 490,806 | 3.16 | 9.40 | 141,282 | 4,613,576 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 95,100 | 2,811,818 | 3.50 | 9.40 | 893,940 | 26,431,089 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 113,529 | 3,557,673 | 3.30 | 9.40 | 1,067,173 | 33,442,126 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,397 | 504,002 | 0.48 | 4.02 | 9,630 | 2,024,828 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,729 | 2,877,893 | 0.66 | 4.02 | 75,244 | 11,561,935 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 113,874 | 3,648,474 | 3.22 | 4.02 | 457,489 | 14,657,744 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,857 | 501,605 | 19.50 | 3.40 | 278,322 | 1,705,507 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 462,056 | 2,859,164 | 19.28 | 3.40 | 1,571,037 | 9,721,444 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 576,097 | 3,534,600 | 19.47 | 3.40 | 1,958,787 | 12,017,993 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,151 | 672,682 | 2.15 | 3.91 | 55,353 | 2,631,263 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79,285 | 3,830,893 | 2.11 | 3.91 | 310,131 | 14,984,921 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98,518 | 4,739,356 | 2.12 | 3.91 | 385,363 | 18,538,465 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,105 | 658,531 | 1.72 | 3.37 | 37,424 | 2,219,249 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,888 | 3,751,608 | 1.24 | 3.37 | 154,643 | 12,642,919 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 71,495 | 4,640,838 | 1.56 | 3.37 | 240,938 | 15,639,624 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 70,921 | 419,748 | 20.33 | 4.00 | 283,684 | 1,678,992 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 400,470 | 2,397,108 | 20.06 | 4.00 | 1,601,880 | 9,588,432 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 496,721 | 2,958,503 | 20.18 | 4.00 | 1,986,884 | 11,834,012 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,868 | 647,426 | 9.82 | 2.70 | 156,244 | 1,748,050 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 331,048 | 3,705,720 | 9.81 | 2.70 | 893,830 | 10,005,444 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 408,592 | 4,569,343 | 9.82 | 2.70 | 1,103,198 | 12,337,226 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 116,552 | 589,558 | 24.64 | 2.60 | 303,035 | 1,532,851 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 610,052 | 3,374,672 | 22.07 | 2.60 | 1,586,135 | 8,774,147 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 872,373 | 4,160,751 | 26.53 | 2.60 | 2,268,170 | 10,817,953 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 504 | 348,827 | 0.14 | 3.85 | 1,940 | 1,342,844 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,913 | 1,996,638 | 0.15 | 3.85 | 11,214 | 7,686,258 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,416 | 2,461,782 | 0.14 | 3.85 | 13,150 | 9,476,876 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,456 | 348,323 | 0.42 | 3.89 | 5,667 | 1,355,708 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,236 | 1,993,725 | 0.41 | 3.89 | 32,055 | 7,759,777 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,389 | 2,458,366 | 0.42 | 3.89 | 40,435 | 9,568,206 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 240 | 346,867 | 0.07 | 3.90 | 935 | 1,351,706 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,133 | 1,985,489 | 0.06 | 3.90 | 4,415 | 7,737,252 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,027 | 2,447,977 | 0.04 | 3.90 | 4,002 | 9,539,522 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,155 | 346,627 | 0.63 | 3.75 | 8,075 | 1,298,915 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 12,899 | 1,984,356 | 0.65 | 3.75 | 48,336 | 7,435,977 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,728 | 2,446,950 | 0.65 | 3.75 | 58,938 | 9,169,456 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,629 | 344,472 | 0.48 | 3.74 | 6,100 | 1,289,944 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 57,723 | 1,971,457 | 3.02 | 3.74 | 216,155 | 7,382,515 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 76,036 | 2,431,222 | 3.23 | 3.74 | 284,732 | 9,104,197 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,200 | 2,355,186 | 0.14 | 3.75 | 11,986 | 8,821,349 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,689 | 342,843 | 1.39 | 3.68 | 17,270 | 1,262,691 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,716 | 1,913,734 | 1.31 | 3.68 | 91,029 | 7,048,282 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 31,007 | 2,351,986 | 1.34 | 3.68 | 114,199 | 8,662,364 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,425 | 338,154 | 7.79 | 3.75 | 91,594 | 1,268,078 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 14,242 | 313,729 | 4.76 | 3.75 | 53,382 | 1,175,919 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 138,609 | 1,889,018 | 7.92 | 3.75 | 519,784 | 7,083,818 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 80,821 | 1,750,409 | 4.84 | 3.75 | 302,933 | 6,560,883 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 168,640 | 2,320,979 | 7.84 | 3.75 | 632,400 | 8,703,671 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 98,333 | 2,152,339 | 4.79 | 3.75 | 368,572 | 8,067,397 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 991 | 299,487 | 0.33 | 3.74 | 3,704 | 1,119,333 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,314 | 1,669,588 | 0.44 | 3.74 | 27,336 | 6,240,085 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,695 | 2,054,006 | 0.38 | 3.74 | 28,760 | 7,676,847 | |
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,128 | 314,139 | -0.36 | 4.50 | -5,075 | 1,413,437 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -25,720 | 2,233,074 | -1.14 | 4.50 | -115,725 | 10,047,493 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -23,152 | 2,385,055 | -0.96 | 4.50 | -104,170 | 10,731,316 | |
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 124,956 | 528,891 | 30.93 | 3.18 | 397,610 | 1,682,931 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 689,834 | 2,955,440 | 30.45 | 3.18 | 2,195,052 | 9,404,210 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 853,956 | 3,639,935 | 30.65 | 3.18 | 2,717,288 | 11,582,273 | |
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -29,450 | 169,589 | -14.80 | 10.70 | -315,230 | 1,815,264 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -158,583 | 952,859 | -14.27 | 10.70 | -1,697,457 | 10,199,307 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -198,256 | 1,178,904 | -14.40 | 10.70 | -2,122,112 | 12,618,871 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,816 | 746,454 | 1.89 | 14.74 | 203,664 | 11,003,628 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,797 | 732,638 | 0.52 | 14.36 | 54,526 | 10,520,975 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,300 | 728,841 | 1.43 | 14.57 | 150,037 | 10,616,808 | |
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 284 | 284 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,143 | 2,143 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,573 | 2,573 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -284,000 | 141,346 | -66.77 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,143,000 | 772,324 | -73.51 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,573,000 | 978,200 | -72.45 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 372 | 597 | 165.47 | 13,000.00 | 4,836,000 | 7,758,569 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 311 | 656 | 89.96 | 13,000.00 | 4,038,398 | 8,527,467 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 718,541 | 3.60 | 14.19 | 354,792 | 10,197,318 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 225 | 225 | 13,000.00 | 2,922,569 | 2,922,569 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -225 | 0 | -100.00 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 345 | 345 | 13,000.00 | 4,489,069 | 4,489,069 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -345 | 0 | -100.00 | ||||
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 120,539 | 6,631,136 | 1.85 | 1.20 | 144,587 | 7,954,048 | |
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 54,461 | 8,485,575 | 0.65 | 1.20 | 65,326 | 10,178,447 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 24,253 | 693,541 | 3.62 | 14.41 | 349,525 | 9,995,035 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,810 | 669,288 | 0.42 | 14.75 | 41,448 | 9,871,998 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,400 | 666,478 | 1.43 | 14.50 | 136,270 | 9,661,798 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 18,081 | 657,078 | 2.83 | 14.54 | 262,972 | 9,556,608 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 32,015 | 638,997 | 5.27 | 14.77 | 472,778 | 9,436,324 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,927 | 606,982 | 1.83 | 14.80 | 161,698 | 8,982,120 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,171 | 596,055 | 0.70 | 14.99 | 62,515 | 8,933,672 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 806 | 591,884 | 0.14 | 14.90 | 12,009 | 8,819,072 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,823 | 591,078 | 0.82 | 14.85 | 71,615 | 8,776,681 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -89,948 | 370,391 | -19.54 | 1.83 | -164,929 | 679,149 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -382,017 | 1,942,764 | -16.43 | 1.83 | -700,466 | 3,562,252 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -430,035 | 2,502,758 | -14.66 | 1.83 | -788,512 | 4,589,057 | |
2018-11-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 100,000 | 6,510,597 | 1.56 | 1.30 | 130,000 | 8,463,776 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,016 | 586,255 | 1.74 | 14.93 | 149,543 | 8,753,022 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,288 | 576,239 | 1.46 | 15.11 | 125,262 | 8,709,046 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 11,396 | 567,951 | 2.05 | 15.24 | 173,680 | 8,655,800 | |
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 556,555 | 4.70 | 15.00 | 374,892 | 8,345,932 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 37,482 | 531,555 | 7.59 | 13.68 | 512,701 | 7,270,928 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,771 | 494,073 | 2.02 | 13.93 | 136,064 | 6,880,115 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 581 | 1,254,993 | 0.05 | 1.35 | 784 | 1,694,241 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,119 | 8,431,114 | 0.05 | 1.35 | 5,561 | 11,382,004 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 5,573 | 1,254,412 | 0.45 | 1.35 | 7,524 | 1,693,456 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 38,001 | 6,410,597 | 0.60 | 1.35 | 51,301 | 8,654,306 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 50,044 | 8,426,995 | 0.60 | 1.35 | 67,559 | 11,376,443 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,648 | 1,248,839 | 7.00 | 1.37 | 111,841 | 1,710,660 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 556,709 | 6,372,596 | 9.57 | 1.37 | 762,580 | 8,729,182 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 733,151 | 8,376,951 | 9.59 | 1.37 | 1,004,270 | 11,474,747 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,849 | 484,302 | 2.29 | 13.82 | 149,986 | 6,695,427 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,141 | 473,453 | 4.67 | 13.31 | 281,361 | 6,301,091 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,074 | 5,815,887 | 0.68 | 1.35 | 52,750 | 7,851,447 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,400 | 7,643,800 | 0.69 | 1.35 | 70,740 | 10,319,130 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 92,960 | 5,776,813 | 1.64 | 1.34 | 124,566 | 7,740,929 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 117,290 | 7,591,400 | 1.57 | 1.34 | 157,169 | 10,172,476 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 562,754 | 5,683,853 | 10.99 | 1.35 | 759,718 | 7,673,202 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 41,454 | 7,474,110 | 0.56 | 1.35 | 55,963 | 10,090,048 | |
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 36,825 | 1,167,191 | 3.26 | 1.65 | 60,761 | 1,925,865 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 158,151 | 5,121,099 | 3.19 | 1.65 | 260,949 | 8,449,813 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 230,555 | 7,432,656 | 3.20 | 1.65 | 380,416 | 12,263,882 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 179,893 | 1,130,366 | 18.93 | 1.65 | 296,823 | 1,865,104 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,419,907 | 4,962,948 | 40.08 | 1.65 | 2,342,847 | 8,188,864 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,916,760 | 7,202,101 | 36.27 | 1.65 | 3,162,654 | 11,883,467 | |
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 188,746 | 188,746 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 705,863 | 705,863 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 1,105,391 | 1,105,391 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -188,746 | 85,038 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -705,863 | 318,021 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -1,105,391 | 498,025 | -68.94 | ||||
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -175,813 | 771,305 | -18.56 | 5.00 | -879,083 | 3,856,602 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -312,266 | 3,186,044 | -8.93 | 5.00 | -1,561,361 | 15,930,539 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -547,860 | 4,682,669 | -10.47 | 5.00 | -2,739,355 | 23,413,813 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -217,256 | 947,118 | -18.66 | 3.10 | -673,494 | 2,936,066 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -808,449 | 3,498,310 | -18.77 | 3.10 | -2,506,192 | 10,844,761 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,204,668 | 5,230,529 | -18.72 | 3.10 | -3,734,471 | 16,214,640 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 97,453 | 950,473 | 11.42 | 2.00 | 194,906 | 1,900,946 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 365,682 | 3,543,041 | 11.51 | 2.00 | 731,364 | 7,086,082 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 546,865 | 5,285,341 | 11.54 | 2.00 | 1,093,730 | 10,570,682 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 62,437 | 853,020 | 7.90 | 1.90 | 118,630 | 1,620,738 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 208,872 | 3,177,359 | 7.04 | 1.90 | 396,857 | 6,036,982 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 228,691 | 4,738,476 | 5.07 | 1.90 | 434,513 | 9,003,104 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -214,336 | 1,164,374 | -15.55 | 2.90 | -621,574 | 3,376,685 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -817,611 | 4,306,759 | -15.96 | 2.90 | -2,371,072 | 12,489,601 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,269,634 | 6,435,197 | -16.48 | 2.90 | -3,681,939 | 18,662,071 | |
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 238,000 | 238,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 861,000 | 861,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 1,338,000 | 1,338,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -238,000 | 59,464 | -80.01 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -861,000 | 216,694 | -79.89 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -1,338,000 | 336,468 | -79.91 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 2,280 | 2,280 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 1,024 | 1,024 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 3,640 | 3,640 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 5,631 | 5,631 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -49 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -48 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -197 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -281 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 699,225 | 1,295,582 | 117.25 | 3.00 | 2,097,675 | 3,886,746 | |
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 483,708 | 483,708 | 3.00 | 1,451,124 | 1,451,124 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 2,109,280 | 2,109,280 | 3.00 | 6,327,840 | 6,327,840 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 3,041,120 | 3,041,120 | 3.00 | 9,123,360 | 9,123,360 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -1,487,294 | 596,357 | -71.38 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -651,074 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -2,295,083 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -3,566,549 | 0 | -100.00 | ||||
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -169,292 | 122,496 | -58.02 | 26.65 | -4,511,632 | 3,264,518 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -445,615 | 632,642 | -41.33 | 26.65 | -11,875,640 | 16,859,909 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -667,949 | 951,300 | -41.25 | 26.65 | -17,800,841 | 25,352,145 | |
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 34,632 | 291,788 | 13.47 | 15.84 | 548,484 | 4,621,192 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 135,206 | 1,078,257 | 14.34 | 15.84 | 2,141,325 | 17,076,895 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,078 | 1,619,249 | 11.12 | 15.84 | 2,566,910 | 25,644,856 | |
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 63,042 | 790,583 | 8.67 | 1.28 | 80,946 | 1,015,109 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 235,326 | 2,968,487 | 8.61 | 1.28 | 302,159 | 3,811,537 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 355,081 | 4,509,785 | 8.55 | 1.28 | 455,924 | 5,790,564 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 28,918 | 727,541 | 4.14 | 1.24 | 35,714 | 898,513 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 394,078 | 2,733,161 | 16.85 | 1.24 | 486,686 | 3,375,454 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 523,601 | 4,154,704 | 14.42 | 1.24 | 646,647 | 5,131,059 | |
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 7,429 | 1,077,694 | 0.69 | 2.41 | 17,920 | 2,599,613 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 11,429 | 1,674,468 | 0.69 | 2.41 | 27,569 | 4,039,152 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 13,337 | 1,070,265 | 1.26 | 2.70 | 36,058 | 2,893,568 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 28,007 | 1,663,039 | 1.71 | 2.70 | 75,720 | 4,496,192 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 3.04 | 25,795 | 903,130 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 3.04 | 91,599 | 3,208,939 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 3.04 | 142,074 | 4,964,121 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 4.00 | 33,984 | 1,189,856 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 4.00 | 120,680 | 4,227,712 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 4.00 | 187,180 | 6,540,128 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 854 | 288,968 | 0.30 | 4.00 | 3,416 | 1,155,872 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 2,884 | 1,026,758 | 0.28 | 4.00 | 11,536 | 4,107,032 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,525 | 1,588,237 | 0.29 | 4.00 | 18,100 | 6,352,948 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,362 | 288,114 | 0.47 | 4.00 | 5,448 | 1,152,456 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,406 | 1,023,874 | 0.43 | 4.00 | 17,624 | 4,095,496 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,380 | 1,583,712 | 0.40 | 4.00 | 25,520 | 6,334,848 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,715 | 201,811 | 0.86 | 2.25 | 3,859 | 454,075 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,359 | 717,089 | 0.89 | 2.25 | 14,308 | 1,613,450 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,732 | 1,109,258 | 0.89 | 2.25 | 21,897 | 2,495,830 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 357 | 286,752 | 0.12 | 3.85 | 1,374 | 1,103,995 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,271 | 1,019,468 | 0.12 | 3.85 | 4,893 | 3,924,952 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,967 | 1,577,332 | 0.12 | 3.85 | 7,573 | 6,072,728 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,064 | 286,395 | 0.37 | 3.85 | 4,096 | 1,102,621 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,873 | 1,018,197 | 0.38 | 3.85 | 14,911 | 3,920,058 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,097 | 1,575,365 | 0.39 | 3.85 | 23,473 | 6,065,155 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,160 | 285,331 | 0.41 | 3.84 | 4,451 | 1,094,815 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,845 | 1,014,324 | 0.38 | 3.84 | 14,753 | 3,891,961 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,774 | 1,569,268 | 0.43 | 3.84 | 25,992 | 6,021,281 | |
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -536 | 49 | -91.62 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -513 | 48 | -91.44 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -2,115 | 197 | -91.48 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -3,011 | 281 | -91.46 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 585 | 585 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 561 | 561 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 2,312 | 2,312 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 3,292 | 3,292 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 357,333 | 2,083,651 | 20.70 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 342,000 | 651,074 | 110.65 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 1,410,000 | 2,295,083 | 159.31 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 2,007,333 | 3,566,549 | 128.74 | ||||
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 20,594 | 284,171 | 7.81 | 3.85 | 79,312 | 1,094,399 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 73,749 | 1,010,479 | 7.87 | 3.85 | 284,022 | 3,891,557 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 113,446 | 1,562,494 | 7.83 | 3.85 | 436,903 | 6,017,477 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 913 | 263,577 | 0.35 | 3.75 | 3,424 | 988,414 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 53,260 | 936,730 | 6.03 | 3.75 | 199,725 | 3,512,738 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 96,736 | 1,449,048 | 7.15 | 3.75 | 362,760 | 5,433,930 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,673 | 200,096 | 1.87 | 2.28 | 8,379 | 456,479 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 13,046 | 710,730 | 1.87 | 2.28 | 29,762 | 1,621,388 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,181 | 1,099,526 | 1.87 | 2.28 | 46,039 | 2,508,349 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,920 | 196,423 | 2.04 | 2.29 | 8,979 | 449,927 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 12,624 | 697,684 | 1.84 | 2.29 | 28,917 | 1,598,115 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 19,206 | 1,079,345 | 1.81 | 2.29 | 43,993 | 2,472,348 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,727 | 192,503 | 1.44 | 2.25 | 6,128 | 432,554 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,023 | 685,060 | 1.48 | 2.25 | 22,522 | 1,539,330 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 15,350 | 1,060,139 | 1.47 | 2.25 | 34,491 | 2,382,132 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,805 | 189,776 | 0.96 | 2.30 | 4,144 | 435,669 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,903 | 675,037 | 1.03 | 2.30 | 15,847 | 1,549,682 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,192 | 1,044,789 | 0.99 | 2.30 | 23,398 | 2,398,522 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,124 | 187,971 | 0.60 | 2.30 | 2,585 | 432,333 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,223 | 668,134 | 0.64 | 2.30 | 9,713 | 1,536,708 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,253 | 1,034,597 | 0.61 | 2.30 | 14,382 | 2,379,573 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,909 | 186,847 | 1.58 | 2.30 | 6,690 | 429,711 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,541 | 663,911 | 1.61 | 2.30 | 24,242 | 1,526,863 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,436 | 1,028,344 | 1.62 | 2.30 | 37,800 | 2,364,986 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5,510 | 183,938 | 3.09 | 2.30 | 12,666 | 422,818 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,897 | 653,370 | 1.07 | 2.30 | 15,854 | 1,501,902 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 24,965 | 1,011,908 | 2.53 | 2.30 | 57,387 | 2,326,073 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 675 | 178,428 | 0.38 | 2.34 | 1,581 | 418,039 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,565 | 646,473 | 0.40 | 2.34 | 6,010 | 1,514,622 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,794 | 986,943 | 0.39 | 2.34 | 8,889 | 2,312,309 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,217 | 177,753 | 3.62 | 2.35 | 14,583 | 416,955 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,092 | 643,908 | 3.55 | 2.35 | 51,821 | 1,510,415 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 33,691 | 983,149 | 3.55 | 2.35 | 79,029 | 2,306,173 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,929 | 171,536 | 2.34 | 2.29 | 8,989 | 392,457 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,274 | 621,816 | 2.35 | 2.29 | 32,657 | 1,422,653 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 21,797 | 949,458 | 2.35 | 2.29 | 49,869 | 2,172,265 | |
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,234 | 2,339,083 | 0.14 | 1.34 | 4,333 | 3,133,669 | |
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,145 | 3,631,103 | 0.03 | 1.34 | 1,534 | 4,864,589 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,205 | 2,335,849 | 0.05 | 1.34 | 1,614 | 3,129,103 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,348 | 3,629,958 | 0.06 | 1.34 | 3,145 | 4,862,692 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 77,076 | 698,623 | 12.40 | 1.34 | 102,943 | 933,081 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 260,046 | 2,334,644 | 12.53 | 1.34 | 347,317 | 3,118,151 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 401,726 | 3,627,610 | 12.45 | 1.34 | 536,545 | 4,845,036 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,244 | 621,547 | 0.36 | 1.35 | 3,040 | 842,134 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,111 | 2,074,598 | 0.39 | 1.35 | 10,990 | 2,810,873 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 11,646 | 3,225,884 | 0.36 | 1.35 | 15,779 | 4,370,750 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 21,021 | 619,303 | 3.51 | 1.36 | 28,555 | 841,261 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 69,041 | 2,066,487 | 3.46 | 1.36 | 93,785 | 2,807,116 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 108,202 | 3,214,238 | 3.48 | 1.36 | 146,982 | 4,366,221 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 47,812 | 598,282 | 8.69 | 1.28 | 61,199 | 765,801 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 150,451 | 1,997,446 | 8.15 | 1.28 | 192,577 | 2,556,731 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 236,393 | 3,106,036 | 8.24 | 1.28 | 302,583 | 3,975,726 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,916 | 550,470 | 0.53 | 1.19 | 3,470 | 655,114 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,586 | 1,846,995 | 1.02 | 1.19 | 22,119 | 2,198,109 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 30,998 | 2,869,643 | 1.09 | 1.19 | 36,891 | 3,415,162 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,161 | 547,554 | 2.85 | 1.18 | 17,958 | 648,578 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,457 | 1,828,409 | 2.95 | 1.18 | 62,135 | 2,165,750 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,276 | 2,838,645 | 2.95 | 1.18 | 96,271 | 3,362,375 | |
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 6,197 | 6,197 | 800.00 | 4,957,600 | 4,957,600 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 1,029 | 1,029 | 800.00 | 823,200 | 823,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 4,519 | 4,519 | 800.00 | 3,615,200 | 3,615,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 5,505 | 5,505 | 800.00 | 4,404,000 | 4,404,000 | ||
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 58,613 | 17,263,200 | 0.34 | 1.22 | 71,338 | 21,011,041 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 32,571 | 3,090,744 | 1.07 | 1.22 | 39,642 | 3,761,745 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 90,049 | 8,850,836 | 1.03 | 1.22 | 109,599 | 10,772,352 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 186,314 | 15,592,160 | 1.21 | 1.22 | 226,763 | 18,977,218 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 8,091 | 17,204,587 | 0.05 | 1.22 | 9,848 | 20,939,703 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 29,655 | 3,058,173 | 0.98 | 1.22 | 36,093 | 3,722,102 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 87,747 | 8,760,787 | 1.01 | 1.22 | 106,797 | 10,662,754 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 508,287 | 15,405,846 | 3.41 | 1.22 | 618,636 | 18,750,455 | |
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 |